Small molecule inhibitors of the prostate cancer target KMT2D

被引:9
|
作者
Yu, Qi [1 ]
Liao, Zonglang [1 ]
Liu, Dan [1 ]
Xie, Wei [1 ]
Liu, Zhongqiu [1 ]
Liao, Guochao [1 ]
Wang, Caiyan [1 ]
机构
[1] Guangzhou Univ Chinese Med, Int Inst Translat Chinese Med, Guangdong Key Lab Translat Canc Res Chinese Med, Joint Lab Translat Canc Res Chinese Med,Minist Ed, Guangzhou 510006, Guangdong, Peoples R China
基金
中国国家自然科学基金;
关键词
KMT2D; Inhibitor; Prostate cancer; Molecular diversity; Drug design; H3K4; METHYLTRANSFERASE; MENIN; PROTEIN; FAMILY; GROWTH; GENE;
D O I
10.1016/j.bbrc.2020.09.004
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Histone lysine N-methyltransferase 2D (KMT2D), an important methyltransferase that is involved in the methylation of lysine 4 in histone H3 (H3K4) and related to the development of prostate cancer. Hypermethylation of H3K4 is shown in prostate cancer (PCa). However, KMT2D inhibitors have not yet been developed. This article aims to design small molecule inhibitors targeting KMT2D_SET to prevent PCa cell proliferation and migration. Twenty-four inhibitors were firstly designed according to a virtual screening of computers, and shown different degrees of binding to KMT2D_SET. Compounds 1 and 16 showed high binding affinities to KMT2D, with KD values of 147 +/- 32.9 mu M and 176 +/- 37.9 mu M, respectively. In addition, they exerted strong inhibitory activity against the PCa cell lines PC-3 and DU145, with IC50 values of 1.1 +/- 0.06 mu M, 1.5 +/- 0.06 mu M and 1.8 +/- 0.1 mu M, 2.3 +/- 0.2 mu M, respectively. Furthermore, these two compounds significantly suppressed the migration of PCa cells. (C) 2020 Elsevier Inc. All rights reserved.
引用
收藏
页码:540 / 547
页数:8
相关论文
共 50 条
  • [21] KMT2D epigenetically regulates p63 target enhancers to coordinate epithelial homeostasis
    Lin-Shiao, E.
    Lan, Y.
    Anderson, A.
    Simpson, C.
    Saffie, R.
    Donahue, G.
    Sen, P.
    Busino, L.
    Garcia, B. A.
    Berger, S.
    Capell, B.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2018, 138 (05) : S106 - S106
  • [22] What Starts Puberty? An Epigenetics Explanation: KMT2D
    Topaloglu, Ali Kemal
    NEUROENDOCRINOLOGY, 2021, 111 (SUPPL 1) : 6 - 7
  • [23] KMT2D promotes proliferation of gastric cancer cells: evidence from ctDNA sequencing
    Li, Qiaolian
    Wu, Riping
    Wu, Fan
    Chen, Qiang
    JOURNAL OF CLINICAL LABORATORY ANALYSIS, 2021, 35 (04)
  • [24] Histone methyltransferase KMT2D mediated lipid metabolism via peroxisome proliferator-activated receptor gamma in prostate cancer
    Zhai, Qiliang
    Luo, Mayao
    Zhang, Yifan
    Zhang, Wenqiang
    Wu, Chenwei
    Lv, Shidong
    Wei, Qiang
    TRANSLATIONAL CANCER RESEARCH, 2022, 11 (08) : 2607 - +
  • [25] A pan-cancer analysis of KMT2D as a potential biomarker for immune checkpoint therapy
    Guan, X.
    Cai, S.
    Wu, X.
    Chen, Y.
    Deng, H.
    Zhong, X.
    Chen, T.
    Huang, M.
    ANNALS OF ONCOLOGY, 2021, 32 : S847 - S847
  • [26] Developing small molecule inhibitors that target androgen receptor signaling in castration-resistant prostate cancer
    Chandrasekaran, Balaji
    Tyagi, Ashish
    Kolluru, Venkatesh
    Vadhanam, Aakash M.
    von Baby, Becca
    Gorle, Suresh
    Sirimulla, Suman
    Ramisetti, Srinivasa R.
    Sharma, Arun K.
    Ankem, Murali K.
    Damodaran, Chendil
    CANCER RESEARCH, 2019, 79 (13)
  • [27] Histone modification by Kmt2c and Kmt2d regulate metastasis in triple-negative breast cancer in vivo.
    Seehawer, Marco
    Li, Zheqi
    Nishida, Jun
    Cejas, Paloma
    Reiter, Andrew
    Goldman, Seth
    Foidart, Pierre
    Rojas, Ernesto
    Papanastasiou, Malvina
    Adelman, Karen
    Long, Henry
    Polyak, Kornelia
    CANCER RESEARCH, 2022, 82 (23)
  • [28] Two Novel KMT2D Gene Variants in Kabuki Syndrome
    Karaer, D. Kan
    Yuksel, Z.
    Karaer, K.
    EUROPEAN JOURNAL OF HUMAN GENETICS, 2019, 27 : 993 - 993
  • [29] The roles of histone methyl-transferase kmt2d in vasculogenesis
    Serrano, Angie
    Demarest, Bradley L.
    Tristani-Firouzi, Martin
    Yost, H. Joseph
    FASEB JOURNAL, 2018, 32 (01):
  • [30] Characteristics of epilepsy in patients with Kabuki syndrome with KMT2D mutations
    Kurahashi, Naoko
    Miyake, Noriko
    Mizuno, Seiji
    Koshimizu, Eriko
    Kurahashi, Hirokazu
    Yamada, Keitaro
    Natsume, Jun
    Aoki, Yusuke
    Nakamura, Miho
    Taniai, Hiroko
    Maki, Yuki
    Abe-Hatano, Chihiro
    Matsumoto, Naomichi
    Maruyama, Koichi
    BRAIN & DEVELOPMENT, 2017, 39 (08): : 672 - 677